Aims and Background: Human leukocyte antigen-G and interleukin-2 receptor play pivotal roles in theproliferation of lymphocytes, and thus generation of immune responses. Their overexpression has been evidencedin different malignant hematopoietic diseases. This study aimed to validate serum soluble human leukocyteantigen-G (sHLA-G) and serum soluble interleukin-2 receptor (sIL-2R) as an additional tool for the diagnosisand follow up of acute lymphoblastic leukemia (ALL). Subjects and
Methods: Both markers were determined byELISA in the serum of 33 ALL pediatric patients before treatment and after intensification phase of chemotherapyas well as in the serum of 14 healthy donors that were selected as a control group.
Results: ALL patients showedabnormal CBC and high serum lactate dehydrogenase, which were improved after chemotherapy. Also, therewas a non-significant increase in serum sHLA-G in ALL patients compared with the control group. However,after chemotherapy, sHLA-G was increased significantly compared with before treatment. On the other hand,serum sIL-2R in ALL patients was increased significantly compared with the control group. After chemotherapy,sIL-2R decreased significantly compared with before treatment.
Conclusions: From these results it could besuggested that measurement of serum sHLA-G might be helpful in diagnosis of ALL, while sIL-2R might beuseful in diagnosis and follow-up of ALL in pediatric patients.